Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Lynn Romejko Jacobs

Lynn Romejko Jacobs

Southern Methodist University USA

Muhammad A Jawad

Muhammad A Jawad

Orlando Regional Medical Center USA

Maria Fernanda Cury-Boaventura

Maria Fernanda Cury-Boaventura

Cruzeiro do Sul University Brazil

Emilio Landolfi

Emilio Landolfi

University of the Fraser Valley Canada

Giuseppe d’Annunzio

Giuseppe d’Annunzio

IRCCS Giannina Gaslini Institute Italy

Charles C. Muscoplat

Charles C. Muscoplat

University of Minnesota USA

Antonino De Lorenzo

Antonino De Lorenzo

University of Rome Tor Vergata Italy

Chaodong Wu

Chaodong Wu

Texas A & M University USA

COPD Congress 2018

About conference

ME Conferences invites all the participants from all over the world to attend 8th International Conference on Chronic Obstructive Pulmonary Disease (COPD) during November 15-16,2018 at Dubai, UAE. This meeting deals with the advanced research technologies in the field of pulmonology and also about the new treatment approaches which are formulated by scientists to treat numerous diseases in easier method which includes encouraging keynote presentation, Oral speech, Poster presentations, Exhibitions.

Main theme of the conference is “Discovering the advances in COPD research”. This would be a two days conference which prompts the minds of attendees.


Why to attend:  

International Conference on Chronic Obstructive Pulmonary Disease aims to bring together globally distinguished academics in the field of Pulmonologists, Pulmonary specialists, Respiratory specialist, Chest medicine specialist, pediatrics pulmonologists, Public Health professionals, Scientists, Academic scientists, Researchers, Intellectuals, to exchange about state of the art Research and Technologies and to bring discoveries of cancer to Patients. To understand the current state of research and the challenges to future discovery.  


Target Audience:

  • Directors/CEO & Research Scientists 
  • Pulmonologists, Respiratory Therapists
  • Lung and respiratory Researchers
  • Respiratory Faculty and Students
  • Lung and Respiratory Associations and Societies
  • Business Entrepreneurs
  • Thoracic surgeons, Radiologists
  •  Medical and Nursing Students, Professors
  • Pharmaceutical companies
  • Manufacturing Medical Devices Companies
  • Pediatrics pulmonologists

Sessions & Tracks

Track 1: Asthma

Asthma is a common inflammatory disease in airways of the lungs. Asthma affects inside of walls of airways are swollen or flamed and causes allergic asthma. Swelling creates the airways even narrower. Cells in the airways tends to cause more mucus production. Secretion is a thick, sticky liquid that can further slender the airways. This chain reaction can result in respiratory disease symptoms and may cause allergic diseases. It is mainly characterized by reversible airflow obstruction, and bronchospasm. Asthma is classified according to the frequency of symptoms, forced expiratory volume in one second, and peak expiratory flow rate. These measures may occur a few times a day or a few times per week. Depending on the person, they may become worse at night or with exercise. Asthma cannot be cured but with better treatment, people can control and active their lives

  • Allergic rhinitis
  • Cough variant
  • Aspirin exacerbated respiratory disease
  • Congestion
  • Occupational asthma

Track 2: Pulmonary Embolism

The blockage of an artery in the lungs by a substance which has moved from elsewhere in the body through the bloodstream or when there is usually a blood clots in lung, blocks the blood flowing through an artery which feeds the lungs. The regularly recurrent symptoms of embolism are characterized by coughing of blood, shortness of breath, chest pain while breathing in and coughing up blood. If the pulmonary embolism is large, it may be capable of such a large mismatch, the patient cannot get enough oxygen into the blood and can be become acutely short of breath. Rapid treatment to break up the clot greatly reduces the danger of death. It can be done with blood thinners and drugs or procedures. Corporal activity Compression stockings can help prevent clots from forming in the first place. Small effusions and lung cancer is caused due to smaller pulmonary emboli which tends to lodge in more exterior areas without collateral circulation they are more likely to the effects which are painful, but not hypoxia, dyspnea or hemodynamic instability such as tachycardia. Larger PEs, which tend to lodge centrally, typically hypoxia, low blood pressure, fast heart rate and fainting, but are often painless because there is no lung infarction due to collateral circulation. The standard presentation for pulmonary embolism with pleuritic pain, dyspnea and tachycardia is likely caused by a large fragmented embolism causing both large and small PEs. The, small PEs are frequently missed because they cause pleuritic pain unaided without any other results and large PEs often missed because they are painless and mimic.

  • Deep vein thrombosis
  • Anticoagulants
  • Pulmonary edema
  • Thrombolytic therapy
  • Post thrombotic syndrome

Track 3: Respiratory Diseases

Respiratory diseases are the common and significant cause of illness and death around worldwide. In the UK, nearly 1 in 7 individuals are affected by some type of chronic lung disease. People with respiratory disease have difficulty respiration from a limitation in processing air out of lungs which further can cause emphysema and chronic bronchitis. The tissues and organs that make exchange of gas probable in higher organisms, and includes conditions of trachea, bronchi, upper respiratory tract, bronchioles, alveoli, pleura and pleural cavity, and the nerves and muscles of breathing occurs in case of uncontrolled conditions. They are characterized by a high inflammatory cell recruitment or destructive cycle of infection. Some of the most common are asthma, chronic obstructive pulmonary disease, pulmonary effusion. As CRDs are not remediable; however, various forms of treatment that help dilate major air passages and improve shortness of breath can help control symptoms and increase the quality of life for people with the diseases.

  • Acute respiratory distress syndrome
  • Respiratory failure
  • Hypersensitivity pneumonitis
  • Pulmonary fibrosis
  • Upper Respiratory tract infections

Track 4: Lung Carcinoma

Lung cancer is the major cause of cancer-related death worldwide. About 85% of cases are related to cigarette smoke and is a malignant tumor categorized by uncontrolled cell growth in tissues of lungs and rarely to other parts of the body. The cases are often caused by a combination of genetic factors and exposure to radon gas, second-hand smoke, asbestos or other forms of air pollution. Lung cancer may be seen on computed tomography and chest radiographs.

Lung cancers are of two types, they grow and spread differently are small cell lung cancer and non-small cell lung cancers. The lungs are giant, tumor grows in them for a prolonged time before they are found. Small-cell lung cancer represents about 15 to 20 %of lung cancers where as Non-Small cell lung cancer represents about 80%. More than two-thirds of nonsmokers having lung cancer are women, and maximum of them posses adenocarcinoma. The general diagnosis of lung cancer is poor because doctors tend not to find the disease until it is at a progressive stage. The survival rate in five year is around 54% for early stage lung cancer that is confined to the lungs, but only around 4% in advanced, inoperable lung cancer.

  • Chemotherapy
  • Radiation therapy
  • Pulmonary lobectomy
  • Mesothelioma
  • Chronic respiratory infections

Track 5: Immune Responses in COPD

In chronic pulmonary disease immune dysfunction occurs. Chronic inflammation contributes to lung damage, consists of innate and adaptive immune responses. extensive immune dysfunction due to the presence and functional activity of T regulatory cells, CD4+ exhausted effector T cells and myeloid-derived suppressor cells. Manipulation of these immunosuppressive networks in COPD could provide a rational strategy to restore functional immune responses, reduce exacerbations, and improve lung function. It facilitates the episodes of respiratory tract infections further proceeds to the pathological appearances of the disease. Inflammation is accompanied by the initiation of defective immune responses that subsidize to worsening the inflammatory lung and disease severity. Advanced approaches to adapt immune responses could be useful in preventing the adverse consequences of most of the inflammatory reactions in the lungs.

  • Influenza
  • Sarcoidosis
  • Albinism
  • Sporadic pulmonary disorders

Track 6:  Epidemiology of COPD

The epidemiological studies of chronic pulmonary disease to quantify the burden of COPD on society and to compare it with various diseases. It is the fourth main cause of death, the spread of the burden of COPD is and will remain a hot topic, as resources for any health intervention are always limited, and they need to be used carefully.  Consequently, COPD is associated with a significant economic burden, including hospitalization, work absence, and disability. Existence rates for people with severe COPD  and pulmonary disease are, in fact, worse than those for people with many common cancers. Cigarette smoking is the fundamental factor, but other factors play a major role in initiating and triggering COPD. Emphasis on the multi-dimensional nature of the problem and an attempt of as long as insight into probable de-bottlenecking to diminish the suffering and pain of millions of COPD patients.  

  • Pulmonary hypertension
  • Prevalence
  •  Mortality and morbidity
  •  Hypoxemia

Track 7: COPD Medications

The medications of pulmonary obstructive disease mitigate the harmful effects that influences difficulty in breathing. Main purpose is to relieve symptoms, minimize the side effects, decrease the risk factors and promote the passage of air through airways into lungs. Advanced medications that help open inflamed lung airways to breathe better and a new class of drugs minimize the risk of pulmonary fibrosis and other related diseases. Even for further progressive stages of disease, operative therapy is accessible that can control symptoms, reduce your risk of complications and exacerbations, and improve the ability to lead an active life.

  • Glucocorticoids
  • Bronchodilators
  • Steroids
  • Antibiotics   
  • Phosphodiesterase inhibitors

Track 8: Prevention and Management of COPD

Chronic obstructive pulmonary disease is mostly generous and is related with an anomalous inflammatory response of the lungs to harmful particles or gases also with prevention and air flow limitation. Public health programs mainly focus on prevention of tobacco use, reducing industrial exposure to chemicals, dusts, other outdoor and indoor air pollutants. Early treatment and control of asthma may avoid the development of COPD. The objective of COPD prevention and management is to recover a patient’s functional status and quality of life by conserving optimal lung function, relieve from symptoms, pulmonary critical care and preventing the recurrence of exacerbations 

  • Pulmonary Rehabilitation
  • Smoking Cessation
  • COPD management
  • Pulmonary Function Test
  • Treatment of exacerbations

Track 9: Pulmonary Hypertension

Pulmonary hypertension is a type of high blood pressure that affects the arteries in lungs and the right side of heart. These are the serious conditions that become progressively worse and are sometimes fatal. These fluctuations can cause the walls of the arteries to become thick and stiff, and extra tissue may form. The blood vessels may also become inflamed and tight. The symptoms are characterized by chest pain, swelling in ankles, legs.  Although some forms of pulmonary hypertension aren't curable, treatment can help lessen symptoms and improve the quality of life. Moreover, pregnancy may have serious threats for women with pulmonary hypertension, so be sure to discuss birth control options with the physician.

  • Gene mutation
  • Congenital heart disease
  • Arrhythmia
  • Angina
  • Liver disease

Track 10: Surgical Interventions and Therapies in COPD

The circumstances of the obstructive pulmonary disease can be prevented by decreasing contact with risk factors. It includes decreasing rates of smoking and improving indoor and outdoor air quality. Regardless of frequent medical treatments, surgery may be measured for the symptomatic patient with medically-optimized, end-stage COPD. Effective management of COPD is based on the ability to slow disease progression, prevent infection, and treat reversible symptoms. If the scope of disease is not completely unalterable (end stage), its progression can be decelerated through smoking reduction and decrease exposure to environmental pollutants or occupational irritants, and long-term therapy with supplemental oxygen. Several agents are available for the management of reversible bronchospasm associated with COPD. People having advanced chronic pulmonary conditions undergo several treatments like bronchoscopy. The goal of surgical interventions and therapy of chronic lung disease is to prolong life by preventing secondary complications, to relieve dyspnea, and to enhance the quality of life by improving functional status.

  • Lung Transplant
  • Bullectomy
  • Oxygen Therapy
  • Lung Volume Reduction Surgery
  • Nicotine Replacement Therapy

Track 11: Pathogenesis of Pulmonary Diseases

COPD is a slowly progressive condition characterized by airflow limitation, which is largely irreversible. It is characterized and defined by limitation of expiratory airflow. The current scenario is chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. The inflammatory mediators, including oxidants and proteases, are believed to play a major role in causing lung injury. Pathogenesis of COPD-an imbalance between proteases and antiproteases and an imbalance between oxidants and oxidative stress in the lungs. The pathological process of chronic lung disease is based on the concept that pulmonary diseases involve stages of commencement by pollutants, infectious agents and exposure to smoke, consolidation and progression. Tissue damage involves complex interactions among oxidative stress, chronic inflammation, extracellular matrix proteolysis, and apoptotic and autophagic cell death.

  • Apoptosis   
  • Hyperinflation
  • Inflammation
  • Vasoconstriction
  • Emphysema

Track 12: Pediatric Pulmonology

The chronic pulmonary disorder is a major risk factor of children’s death. Series of studies on pediatric pulmonary disorder indicates overlapping age groups from birth to late middle age that early life event which includes antenatal influences on lung growth and programs the child at increased risk for future COPD. Various signs are phlegm production, chronic cough, frequent lung infections, and difficulty doing daily activities because of breathlessness. Pediatric pulmonology is based on diagnosis, treatment, and accomplish children from birth to 21 years old with breathing and lung diseases. The COPD disorders in infants like pneumonia, asthma, tuberculosis, complicated chest infections are cured pediatric pulmonologists.

  • Tuberculosis
  • Dysplasia
  • Interstitial lung disease
  • Cystic fibrosis
  • Recurrent aspiration




Market Analysis

Scope and Importance:

According to the global COPD market research was estimated to be assets of $11.3 billion and, the prediction to scope a value of $15.6 billion by 2019. Rapid growth of the pulmonary disease will be driven by a great number of new, more suitable and effectual yields entering the market and imposing greater value compared to the remedies that are already available in the market. Daily once LABA/LAMA, fixed-dose combinations of drugs (QVA-149) are now driving the growth of this disease.

Global Smart Inhalers Market is dignified to rise at a CAGR of about 64.5% over the next decade to extent approximately $854 million by 2025.


Why Dubai?

Dubai is a world city and business hub of the Middle East. It is located on the southeast coast of the Persian Gulf. UAE is able to command healthcare standards according to their internal laws, although the standards and regulations rarely have extreme differences. Moreover Emirates offer the convenience of a wide range of primary care services, in addition to emergency treatment of chronic diseases. To ease the growing pressure on the healthcare system, the GCC governments are injecting huge funds as well as encouraging private sector participation to build hospitals and clinics, upgrade the existing infrastructure, and match the quality of services offered in developed countries Compulsory health insurance schemes has been made mandatory for all the people in Dubai in order to drive sustainability.

  • Burj khalifa
  • Jumeriah mosque
  • Miracle garden
  • Ferrari world
  • Hatta Rock Pools
  • Emirate Towers
  • Dubai Marina Walk
  • Dubai Mosque
  • Atlantis Palm Jumeriah
  • Dubai Creek Golf and Yacht Club
  • Dubai Aquarium and Underwater Zoo
  • Palm Jumeriah
  • Burj Al Arab beach
  • Dubai Marina Walk
  • Burj Al Arab-The tower of Arabs

Conference Highlights:

  • Asthma
  • Pulmonary Embolism
  • Respiratory Diseases
  • Lung Carcinoma
  • Immune Responses in COPD
  • COPD Medications
  • Prevention and Management of COPD
  • Pulmonary Hypertension
  • Surgical Interventions and Therapies in COPD
  • Pathogenesis of Pulmonary Diseases
  • Paediatric Pulmonology 

Hospitals in Worldwide:

  • Mayo Clinic
  • Cleveland Clinic
  • Massachusetts General Hospital
  • UCSF Medical Center
  • University of Michigan Hospitals and Health Centers
  • Barnes-Jewish Hospital
  • Penn Presbyterian Medical Center
  • UCLA Medical Center
  • Johns Hopkins Hospital
  • Duke University Hospital
  • UC San Diego Health-UC San Diego Medical Center
  • Houston Methodist Hospital
  • Scripps Green Hospital
  • New York-Presbyterian Hospital
  • University of Alabama at Birmingham Hospital
  • Yale-New Haven Hospital

Hospitals in Middle East:

  • King Faisal Specialist Hospital & Research Centre
  • Saudi Center for Organ Transplantation
  • Memorial Hospital
  • Avicenna Research Institute
  • Cancer Therapy Institute Research Centre
  • Mediclinic Middle East (EHL HealthCare Management Services)
  • Tawam Hospital
  • International Hospital of Bahrain
  • Milad Hospital

Hospitals in Dubai:

  • Zulekha hospital
  • Al Zahra hospital, Dubai
  • Canadian Specialist Hospital
  • American Hospitals, Dubai
  • Dubai Hospital
  • Saudi German Hospitals
  • Medcare Hospitals, Dubai
  • Emirates Hospitals
  • Burjeel Hospital for Advanced Surgery, Dubai
  • International Modern Hospital, UAE

Figure 1:

Top Universities Globally in Respiratory Research:

  • The University of Edinburgh
  • The University of Manchester
  • London School of Hygiene and Tropical Medicine
  • Queen Mary University of London
  • The University of Nottingham
  • The University of Sheffield
  • University of Birmingham
  • University of Bristol
  • University of Dundee
  • University of Glasgow
  • University of Leeds
  • University of Liverpool
  • University of Southampton
  • Newcastle University
  • The University of Warwick
  • University of Aberdeen
  • Cardiff University
  • Kings College London
  • Imperial College London
  • UCL (University College London)
  • University of Cambridge
  • University of Oxford
  • University of East Anglia (UEA)
  • University of York 


Universities in Middle East:

  • Columbia University Middle East Research Center
  • Gulf Medical University
  • Middle East Institute of Health - University Hospital
  • Tehran University of Medical Sciences
  • Shahid Beheshti University of Medical Sciences and Health Services
  • Ain Shams University
  • Jordan University of Science and Technology
  • Mohammed Bin Rashid University Of Medicine and Health Sciences
  • King Abdullah University of Science and Technology

Universities in Dubai:

  • Mohammad Bin Rashid University of Medicine and Health Sciences
  • Royal College of Surgeons in Ireland (RCSI) Institute of Leadership
  • European University College
  • Hamdan Bin Mohammad Smart University
  • Canadian University in Dubai

Market Shares of COPD and Asthma:

According to the current research Global Asthma and COPD Therapies market shares in coming years is expected to be increased by the percentage. As now US is the highest developing therapeutics for the chronic respiratory disorders is 40% all over the world.

Figure 2:

Societies in Worldwide:

•           Algerian Society of Pneumology

•           Asociación Argentina de Medicina Respiratoria

•           Thoracic Society of Australia and New Zealand

•           Austrian Society for Pneumology

•           Belgian Thoracic Society

•           Bulgarian Respiratory Society

•           Canadian Thoracic Society

•           Chinese Thoracic Society

•           Croation Respiratory Society

•           Egyptian Paediatric Pneumology Society

•           Forum of International Respiratory Societies

•           Russian Respiratory Society

•           Peruvian Society of Pneumology

•           German Center for Lung Research

Middle East societies in Lung and Respiratory care:

  • Emirates Radiology Society
  • Emirates Neonatal Pediatric Society
  • Emirates Pharmacy Society
  • Emirates Allergy and Respiratory Society

 Dubai Societies in Lung and Respiratory care:

  • European Society of  Thoracic Congress
  • European Respiratory Society
  • Saudi Thoracic Society
  • Gulf Thoracic Society

Leading causes of death in worldwide

Over the million deaths worldwide, more than half (54%) were due to the top 10 causes. Ischaemic heart disease and stroke are the world’s biggest killers, another main reason accounting for death is Chronic Obstructive Pulmonary Disease. These diseases have remained the leading causes of death globally in the last 15 years.

Figure 3:




Worldwide Associations in Lung and Respiratory care:

  • Cambridge Development Initiative
  • Cambridge Graduate Course in Medicine Society
  • Cambridge Romanian Society
  • Research Drones Society, Oxford
  • Midland Geotechnical Society – UK
  • Palaeontological Association – UK
  • The British Hospitality Association
  • National Housing Federation
  • Self-Storage Association UK
  • Lung Health UK
  • British Lung Foundation
  • British Thoracic Society
  • British Association for Lung Research
  • The Sarcoidosis charity
  • The Freeman Heart & Lung Transplant Association
  • British Snoring and Sleep Apnoea Association
  • Association of Respiratory Nurses (ARNS)
  • Association of charted Physiotherapists in respiratory care (ACPRC)

Risk factors of Chronic Respiratory Diseases:

 In addition to tobacco smoke, other risk factors include air pollution, occupational chemicals and dusts, and frequent lower respiratory infections during childhood. CRDs are not curable, however, various forms of treatment that help dilate major air passages and improve shortness of breath can help control symptoms and increase the quality of life for people with the disease

Figure 4:


Industries Associated with Lung and Respiratory Care Worldwide:

  • GlaxoSmithKline
  •  Pfizer
  •  Sanofi-Aventis
  •  AstraZeneca
  •  Novartis
  • Roche
  •  Wyeth
  •  Merk & Co
  •  Lilly
  •  Boehringer Ingelheim
  •  Johnson & Johnson
  •  Schering Plough
  •  Novo Nordisk
  •  Bayer Schering
  •  Abbott
  •  Teva
  •  Bristol-Myers Squibb
  •  Mundi Int
  •  Gilead Sciences
  • Servier
  • Edwards Lifesciences
  • British American Tobacco
  • Imperial Tobacco Group
  • Reckitt Benckiser Group
  • Acm Global Central Laboratory Services Ltd
  • Acorn Polymers (UK) Ltd
  • Access Health Products
  • Acm Global Central Laboratory Services Ltd
  • Acorn Equipment Co Ltd

Industries in Middle East:

  • Neo Pharmaceutical plant, UAE
  • Med Pharma
  • Pfizer, UAE
  • Merck, UAE
  • Ranbaxy Laboratories Limited
  • Himka Pharmaceuticals Limited
  • Elis Pharmaceutical Limited
  • Gen Pharma
  • Amgen

Industries in Dubai:

  • Dayarm Pharma
  • Julphar Life
  • Novo Nordisk
  • Pharma Gulf Fz LIC
  • Abbott Laboratories S.A.
  • Sanofi Aventis UAE
  • Alliance Global
  • Glaxo Smith Kine
  • Saga Pharmaceuticals


European Societies:

European Idiopathic Pulmonary Fibrosis & Related Disorders FederationEuropean Respiratory Society; Italian Society for Infant Respiratory DiseasesItalian Society of PneumologyRomania European Society for Pediatric Research  (ESPR)European Association for BronchologyJordan Thoracic SocietyItalian Respiratory SocietySaudi Thoracic SocietyFinnish Respiratory SocietyGerman Respiratory Society

USA Societies:

Canadian Thoracic SocietyBrazilian Society of Pneumology and TisiologyArgentine Association of Respiratory MedicineAmerican Thoracic SocietyCanadian Lung AssociationRussian Respiratory SocietyChinese Association of Chest PhysiciansChinese Thoracic SocietyInfectious Diseases Society of AmericaAmeican Lung AssociationInternational Association For The Study Of Lung CancerAmerican Cancer SocietyAmerican Association for Respiratory Care


Asian Societies:

Asian Pacific Society of RespirologyTurkish Respiratory SocietyKorean Academy of Tuberculosis and Respiratory DiseasesJapanese Respiratory SocietyChinese Association of Chest PhysiciansIndian Chest SocietyAsian Society of Thoracic SurgeryAsian Society for Cardiovascular and Thoracic SurgeryMalaysian Thoracic SocietyAsian Paediatric Pulmonology Society (APPS)

Middle East Societies:

Saudi Thoracic Society; Saudi Society for Respiratory Care; Saudi Association for Pulmonary Hypertension (SAPH); Israeli Society for Infectious Diseases; Emirates Allergy and Respiratory SocietyGulf Thoracic Society; Lebanese Pulmonary Society; Turkish Thoracic Society; Turkish Respiratory Society

 Related Conferences:

Past Conference Report

COPD 2017

ME Conferences successfully hosted "4th International conference on Chronic obstructive pulmonary disease" during May 29-31, 2017 Osaka, Japan.COPD 2017 conference was organized around the theme "Reviving new aspects to explore the innovative strategies: The next decade in COPD" and it was a great success where eminent keynote speakers from various reputed organizations made their resplendent presence and addressed the gathering.

COPD 2017 was marked by the attendance of Editorial Board Members of supported Journals like Journal of Pulmonary & Respiratory Medicine, Journal of Lung Diseases & Treatment and Journal of Pulmonary Medicine. Many Scientists, young and brilliant Researchers, Business Delegates and talented Student Communities representing from varies countries made this conference fruitful and productive driving the three-day event into the path of success with thought-provoking keynote and plenary presentations.

4th International Conference on Chronic Obstructive Pulmonary Disease covered the following scientific sessions and discussions:


• Epidemiology of COPD

• Diagnostic Evaluation of COPD

• COPD Therapeutics

• COPD Exacerbations

• Self-Management and Prevention of COPD

• COPD Complications

• Management of COPD

• CO-Morbidities in COPD


COPD 2017 Organizing Committee would like to thank the Moderator of the conference.

Yong –Xiao Wang

Albany Medical College, USA

Nobuaki Miyahara

Okayama University, Japan

Hiroaki Kume

Kindai University, Japan

With the feedback from the participants and supporters of COPD 2017, we are glad to announce 8th International Conference on Chronic Obstructive Pulmonary Disease (COPD Congress 2018) during November 15-16, 2018 at Dubai, UAE. COPD Congress 2018 will cover some of the most challenging topics and advancements in research in the fields of Pulmonary and Respiratory medicine.

Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date November 15-16, 2018

Speaker Opportunity

Supported By

Journal of Pulmonary & Respiratory Medicine Journal of Lung Diseases & Treatment Journal of Pulmonary Medicine

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by

Media partners & Collaborators & Sponsors




Media Partner


Media Partner


Media Partner


Media Partner


Media Partner


Media Partner




Media Partner




Media Partner



Past Affiliations

Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos


  • Airway Injury
  • Antibiotic
  • Anticholinergics
  • Arthritis
  • Asthma Cough
  • Asthma In Pregnancy
  • Atelectasis
  • Bacterial Colonization
  • Bacterial Pathogens
  • Beta-agonists
  • Blood Granulocytes
  • Bronchial Infection
  • Bronchiestasis
  • Bronchodilators
  • Cancer
  • Cardiovascular Diseases
  • Chest Radiography
  • Chronic Airflow Obstruction
  • Chronic Bronchitis
  • Chronic Kidney Disease
  • Chronic Low-level Inflammation
  • Chronic Pain
  • Comorbid
  • Congestive Heart Failure
  • COPD Diagnosed
  • Corticosteroids
  • Cystic Fibrosis
  • Drug Allergy
  • Dyspnea
  • Dyspnea
  • Emphysema
  • Exacerbation
  • Exacerbations
  • Fatal To Chronic
  • Heart Attacks
  • Heart Failure
  • Hyperventilation
  • Hypoxia
  • Inflammatory Response
  • Influenzae
  • Inhaler
  • Intersticial Lung Disease
  • Liquid Oxygen (LOX)
  • Lung
  • Lung Asthma
  • Lung Cancer
  • Lung Immunology
  • Lung Transplant
  • Non-Alcoholic Fatty Liver Disease (NAFLD)
  • Oxygen Concentrator
  • Oxygen Therapy
  • Pathogenesis
  • Pathophysiology Of Chronic Asthma
  • Pediatric Allergist
  • Phagocytosis
  • Pleural Effusion
  • Pneumonia
  • Pulmonary And Critical Medicine
  • Pulmonary Embolism
  • Pulmonary Hypertension
  • Pulmonary Therapy
  • Pulmonary Vascular Diseases
  • Pulse Oximetry
  • Respiratory Asthma
  • Respiratory Diseases
  • Rhinitis Allergy Symptoms
  • Smoking
  • Spirometry
  • Sputum
  • Stroke
  • Thoracostomy
  • Tracheobronchial
  • Tuberculosis
  • Viral Diseases